Literature DB >> 16406348

Immune system evasion by peripheral nerve sheath tumor.

Philip R Lee1, Jonathan E Cohen, R Douglas Fields.   

Abstract

Mechanisms by which tumor cells evade detection by the host's immune system are thought to play a role in progression to malignancy, but this has not been investigated in the context of neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant disorder, in which aggressive peripheral nerve tumors, known as malignant peripheral nerve sheath tumors (MPNSTs), develop in 5-10% of patients. Large scale gene expression profiling of a MPNST-derived cell line, T265, and normal human Schwann cells (hSCs) identified a large group of immune function genes down-regulated in T265 cells. Here we report that the aberrant expression of immune system related genes extends beyond MHC class I and II genes in T265 cells to include a transcription factor (MHC2TA) and other critical components of the antigen processing and presentation apparatus. TAP1, the transporter-activator protein that loads peptide antigens onto MHC class I molecules, is down-regulated, and CD74, a chaperone protein whose function is in processing and transport of MHC class II molecules, is down-regulated and alternatively spliced to produce an RNA transcript not evident in normal human Schwann cells. These findings reveal multiple molecular pathways and at least two cellular mechanisms acting to reduce the normal immune system molecules involved in antigen processing and presentation in cells derived from a peripheral nerve sheath tumor. Acquiring a "silent" immune signature may be a critical step in the progress towards malignancy in MPNSTs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406348      PMCID: PMC2265633          DOI: 10.1016/j.neulet.2005.12.027

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Multiple roles of the invariant chain in MHC class II function.

Authors:  Pamela Stumptner-Cuvelette; Philippe Benaroch
Journal:  Biochim Biophys Acta       Date:  2002-01-30

2.  Application of z-score transformation to Affymetrix data.

Authors:  Chris Cheadle; Yoon S Cho-Chung; Kevin G Becker; Marquis P Vawter
Journal:  Appl Bioinformatics       Date:  2003

3.  Transcriptional profiling in an MPNST-derived cell line and normal human Schwann cells.

Authors:  Philip R Lee; Jonathan E Cohen; Elisabetta A Tendi; Robert Farrer; George H DE Vries; Kevin G Becker; R Douglas Fields
Journal:  Neuron Glia Biol       Date:  2004-05

4.  Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma.

Authors:  L Kluwe; R Friedrich; V F Mautner
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

Review 5.  TAP off--tumors on.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  1997-06

6.  Structure of the human Ia-associated invariant (gamma)-chain gene: identification of 5' sequences shared with major histocompatibility complex class II genes.

Authors:  D M O'Sullivan; D Larhammar; M C Wilson; P A Peterson; V Quaranta
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

7.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

8.  Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis.

Authors:  A Badache; N Muja; G H De Vries
Journal:  Oncogene       Date:  1998-08-13       Impact factor: 9.867

9.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.

Authors:  E Legius; D A Marchuk; F S Collins; T W Glover
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

Review 10.  Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes.

Authors:  Salomé LeibundGut-Landmann; Jean-Marc Waldburger; Michal Krawczyk; Luc A Otten; Tobias Suter; Adriano Fontana; Hans Acha-Orbea; Walter Reith
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

View more
  6 in total

1.  Occipital peripheral nerve stimulation in the management of chronic intractable occipital neuralgia in a patient with neurofibromatosis type 1: a case report.

Authors:  Ioannis Skaribas; Octavio Calvillo; Evangelia Delikanaki-Skaribas
Journal:  J Med Case Rep       Date:  2011-05-10

Review 2.  Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.

Authors:  Nevena Tzekova; André Heinen; Patrick Küry
Journal:  J Clin Immunol       Date:  2014-04-17       Impact factor: 8.317

3.  Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Authors:  Kellie B Haworth; Michael A Arnold; Christopher R Pierson; Kwangmin Choi; Nicholas D Yeager; Nancy Ratner; Ryan D Roberts; Jonathan L Finlay; Timothy P Cripe
Journal:  Oncotarget       Date:  2017-05-30

4.  ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Authors:  Dane A Hayes; Dale A Kunde; Robyn L Taylor; Stephen B Pyecroft; Sukhwinder Singh Sohal; Elizabeth T Snow
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

5.  Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.

Authors:  Elizabeth Shurell; Arun S Singh; Joseph G Crompton; Sarah Jensen; Yunfeng Li; Sarah Dry; Scott Nelson; Bartosz Chmielowski; Nicholas Bernthal; Noah Federman; Paul Tumeh; Fritz C Eilber
Journal:  Oncotarget       Date:  2016-09-27

6.  Neurofibromin 1 Impairs Natural Killer T-Cell-Dependent Antitumor Immunity against a T-Cell Lymphoma.

Authors:  Jianyun Liu; Richard M Gallo; Masood A Khan; Gourapura J Renukaradhya; Randy R Brutkiewicz
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.